ASTM drops as the short ratio increases to 14.40% from 3.33M, the previous month to 4.06M shares and more … Read more…
ASTM is restating its financial statements included in an amended annual report on Form 10-K/A Read more…
On 2/9/11, WBB Securities initiated with a SELL rating and a 12 mo price target price of $2.00. Read more…
New proxy to increase number of authorized shares to raise additional capital or acquire another company Read more…
National Securities downgraded shares of Aastrom Biosciences (ASTM) to a “NEUTRAL” rating Read more…
Previously reported interim results from the US Phase 2b RESTORE-CLI clinical trial Read more…
US Phase 2 IMPACT-DCM clinical trial results were reviewed at The Sixth International Conference on Cell Therapy for Cardiovascular Disease in NYC, NY, Read more…
ASTM has been granted a US patent which provides composition of matter protection for its investigational expanded autologous cell therapy product. Read more…
Juventas Therapeutics has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia (CLI) patients. Read more…
ASTM has completed a public offering at a price of $2.25 per unit Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.